From left to right: Lou Tartaglia, Richard Lim and Dave Fallace (Cure Ventures)

April 4, 2023 07:00 AM EDT

The ‘new, old kids’ on the biotech block unveil a $350M stealth science fund. And they’re going very, very early

Richard Lim and his two co-founders at Cure Ventures have some biotech stories to tell.

Lim recalls the time some 17 years ago he and …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Corvus' early-phase atopic dermatitis data prompt stock rally

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

GSK awaits Nucala decision after FDA target date passes

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges